US industry seeks R&D policy for India's pharma sector ahead of Budget 2023

Q: How long will it take to read this news story?

The story "US industry seeks R&amp;D policy for India&#039;s pharma sector ahead of Budget 2023" has 379 words across 17 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "US industry seeks R&amp;D policy for India&#039;s pharma sector ahead of Budget 2023" was covered 1 months ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 167 news stories per day. It's most recent story was published 6 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #4876879</li><li>URL: https://beamstart.com/news/us-industry-seeks-rd-policy-16748831618382</li></ul>

Business Standard Logo Business Standard 1 mo ago

US industry seeks R&D policy for India's pharma sector ahead of Budget 2023 - Business Standard

Quick Summary:

It is time that the government of India comes out with a research and development policy for the pharmaceutical sector, Karun Rishi, president of USA-India Chamber of Commerce (USAIC) told PTI.

Ahead of the Union Budget 2023-24, the US pharma industry has said that India should come out with a research and development policy for its pharmaceutical sector.

Based out of Boston, the USAIC for the last 16 years has been organising the India-US health care summit which is attended by the who's who of the pharma sector from both India and the United States.